Grant Details
Description
The capacity to catalyze recombination at designated genomic sites in the
mouse germline would provide the means for engineering specific
rearrangements. Specifically, deletions and duplications of defined
regions and integration at specific sites will answer a variety of
questions.
Among these specific questions are the mapping of the genes responsible
for the pleiotropic phenotypes of Down's Syndrome, recapitulated in a
murine segmental trisomy and the deletion mapping of promoter elements
at the enkephalin locus.
Recently, the bacteriophage P1 Cre recombinase has been shown to be
active in catalyzing recombination between lox sites in mammalian cells,
including pluripotent embryonic stem cells and mouse oocytes.
We are using this system, first to engineer specific segmental
duplications on mouse chromosome 16 and, second, to introduce specific
promoter deletions of the enkephalin gene at the HPRT locus.
In the first part of the project, lox sites will be introduced by
homologous recombination at specific sites on chromosome 16 in embryonic
stem cells. Recombination between these sites will then be catalyzed by
the Cre recombinase in embryonic stem cells and in oocytes.
In the second part of the project, a lox site has been introduced at the
HPRT. Further, promoter deletions of the enkephelin locus have been
constructed in plasmid sectors with lox sites. The plasmids will be
integrated at the HPRT site by cotransfection into the embryonic stem
cell lines with a Cre expressing plasmid.
While these experiments do not exhaust the possibilities of this
approach, they will demonstrate its effectiveness for further
applications.
Status | Not started |
---|
Funding
- National Institute of Mental Health
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.